Published in Prostaglandins Other Lipid Mediat on April 19, 2009
Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature (2017) 2.01
LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell Metab (2013) 1.39
Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. J Biol Chem (2011) 1.13
Emerging roles for lysophosphatidylserine in resolution of inflammation. Prog Lipid Res (2012) 1.03
Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum (2011) 0.94
Neutrophils regulate tissue Neutrophilia in inflammation via the oxidant-modified lipid lysophosphatidylserine. J Biol Chem (2013) 0.92
Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PLoS One (2014) 0.87
Characterization of Imidazopyridine Compounds as Negative Allosteric Modulators of Proton-Sensing GPR4 in Extracellular Acidification-Induced Responses. PLoS One (2015) 0.87
Functional metagenomic discovery of bacterial effectors in the human microbiome and isolation of commendamide, a GPCR G2A/132 agonist. Proc Natl Acad Sci U S A (2015) 0.86
LC-MS-based metabolomic analysis of serum and livers from red ginseng-fed rats. J Ginseng Res (2013) 0.83
Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine. Inflamm Res (2012) 0.82
CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury. J Lipid Res (2013) 0.82
Ionotropic and metabotropic proton-sensing receptors involved in airway inflammation in allergic asthma. Mediators Inflamm (2014) 0.82
Lysophosphatidylcholine: A Novel Modulator of Trypanosoma cruzi Transmission. J Parasitol Res (2011) 0.81
Metabolomics changes in a rat model of obstructive jaundice: mapping to metabolism of amino acids, carbohydrates and lipids as well as oxidative stress. J Clin Biochem Nutr (2015) 0.80
Metabolite Modulation in Human Plasma in the Early Phase of Acclimatization to Hypobaric Hypoxia. Sci Rep (2016) 0.79
Structural and functional analysis of a platelet-activating lysophosphatidylcholine of Trypanosoma cruzi. PLoS Negl Trop Dis (2014) 0.78
Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis. PLoS One (2016) 0.78
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. Elife (2016) 0.78
Intercellular Lipid Mediators and GPCR Drug Discovery. Biomol Ther (Seoul) (2013) 0.77
Three plasma metabolite signatures for diagnosing high altitude pulmonary edema. Sci Rep (2015) 0.76
Lipid response patterns in acute phase paediatric Plasmodium falciparum malaria. Metabolomics (2017) 0.75
G2A Signaling Dampens Colitic Inflammation via Production of IFN-γ. J Immunol (2016) 0.75
The molecular mechanism by which saturated lysophosphatidylcholine attenuates the metastatic capacity of melanoma cells. FEBS Open Bio (2016) 0.75
Metabolite and Lipid Profiling of Biobank Plasma Samples Collected Prior to Onset of Rheumatoid Arthritis. PLoS One (2016) 0.75
Here, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas Disease. Front Immunol (2016) 0.75
Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A (2017) 0.75
Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation. Sci Rep (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Acute-phase proteins and other systemic responses to inflammation. N Engl J Med (1999) 18.25
Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14
The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 5.74
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res (2004) 4.67
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell (2003) 3.68
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest (2005) 3.25
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (2006) 2.90
Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A (1988) 2.83
Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med (2004) 2.71
Retracted Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (2001) 2.52
Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol (2008) 2.42
Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res (2007) 2.39
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Phospholipid precursors of prostaglandins. Biochim Biophys Acta (1968) 1.90
Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res (2008) 1.84
Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun (2005) 1.83
Migration to apoptotic "find-me" signals is mediated via the phagocyte receptor G2A. J Biol Chem (2007) 1.75
Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol (2000) 1.73
Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med (2004) 1.72
I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med (2002) 1.63
High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev (2002) 1.58
Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity (2001) 1.58
Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol (2008) 1.56
ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells. Arterioscler Thromb Vasc Biol (2009) 1.55
Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem (2007) 1.53
Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48
Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron (2004) 1.46
Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res (2005) 1.43
Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J (2008) 1.43
Oxidation-specific epitopes are important targets of innate immunity. J Intern Med (2008) 1.41
Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol (2009) 1.38
Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A (2006) 1.38
T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc Natl Acad Sci U S A (2003) 1.37
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit (2005) 1.37
Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes. Proc Natl Acad Sci U S A (2007) 1.33
Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood (2004) 1.31
Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc Natl Acad Sci U S A (1990) 1.28
The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem (2005) 1.27
Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res (2002) 1.19
A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc Natl Acad Sci U S A (1998) 1.18
HMGB1 as a potential therapeutic target. Novartis Found Symp (2007) 1.17
NADPH oxidase-dependent generation of lysophosphatidylserine enhances clearance of activated and dying neutrophils via G2A. J Biol Chem (2008) 1.16
Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem (2005) 1.15
Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol (1998) 1.14
The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol (2005) 1.11
Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol Biol Cell (2005) 1.10
G2A as a receptor for oxidized free fatty acids. Prostaglandins Other Lipid Mediat (2008) 1.10
Direct genetic demonstration of G alpha 13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent actin rearrangement. Proc Natl Acad Sci U S A (2000) 1.08
Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol (2006) 1.07
Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta (2005) 1.06
Secretory phospholipase A2. Biol Pharm Bull (2004) 1.05
Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. Glia (2003) 1.05
Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice. J Lipid Res (2005) 1.04
Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res (2000) 1.02
G2A plays proinflammatory roles in human keratinocytes under oxidative stress as a receptor for 9-hydroxyoctadecadienoic acid. J Invest Dermatol (2007) 1.01
Identification of poly-reactive natural IgM antibody that recognizes late apoptotic cells and promotes phagocytosis of the cells. Apoptosis (2007) 1.01
The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis. J Biol Chem (2003) 0.99
Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry (2006) 0.97
Lysophosphatidylcholine modulates neutrophil oxidant production through elevation of cyclic AMP. J Immunol (2005) 0.97
Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol (2007) 0.97
G2A is an oncogenic G protein-coupled receptor. Oncogene (2000) 0.97
Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci (2007) 0.96
Retraction. Science (2005) 0.96
Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci (2007) 0.95
Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol (1986) 0.94
Albumin inhibits cytotoxic activity of lysophosphatidylcholine by direct binding. Prostaglandins Other Lipid Mediat (2006) 0.93
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell (2002) 0.92
Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem (2005) 0.92
Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine (2005) 0.92
Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus (1998) 0.92
Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol (2006) 0.91
Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) (2008) 0.91
Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ Res (2000) 0.90
G2A deficiency in mice promotes macrophage activation and atherosclerosis. Circ Res (2008) 0.89
Lysophosphatidylcholine up-regulates CXCR4 chemokine receptor expression in human CD4 T cells. J Leukoc Biol (2004) 0.85
Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery. Pharmacol Ther (2008) 0.85
Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus (1999) 0.81
Deletion of the G2A receptor fails to attenuate experimental autoimmune encephalomyelitis. J Neuroimmunol (2009) 0.80
Apoptosis and autoimmunity. Curr Opin Nephrol Hypertens (1997) 0.76